Recently, Guangzhou Pharmaceutical Holdings Limited (GPHL) announced plans to invest RMB 10 billion to 15 billion over the next few years to drive its innovation-led transformation. This strategic move aims to accelerate the company’s evolution from a traditional pharmaceutical enterprise into a technology-driven, integrated health and wellness platform. Key investment areas will include biopharmaceuticals, modernization of traditional Chinese medicine, digital health, smart manufacturing, and international expansion. GPHL stated that this initiative not only aligns with China’s ‘Healthy China 2030’ national strategy but also positions the company to seize opportunities amid global shifts in the healthcare and pharmaceutical industries. By significantly increasing R&D spending, attracting top-tier talent, building innovation platforms, and deepening industry-academia collaborations, GPHL seeks to establish a globally competitive health ecosystem. Additionally, the group will expedite its digital transformation by leveraging AI and big data to optimize R&D processes and supply chain management, thereby enhancing operational efficiency and product innovation. This multi-billion-yuan investment marks a new phase of high-quality growth for GPHL and may serve as a model for the broader transformation of China’s pharmaceutical sector.
近日，广药集团宣布计划在未来几年内投入100亿至150亿元人民币，用于推动企业创新转型。这一战略举措旨在加速其从传统制药企业向科技驱动型大健康综合平台的升级。投资将重点布局生物医药、中医药现代化、数字医疗、智能制造以及国际化发展等领域。广药集团表示，此举不仅是为了响应国家‘健康中国2030’战略，更是为了在全球医药健康产业变革中抢占先机。通过加大研发投入、引进高端人才、建设创新平台和深化产学研合作，广药希望打造具有全球竞争力的医药健康生态体系。此外，集团还将加快数字化转型，利用人工智能、大数据等技术优化研发流程与供应链管理，提升运营效率与产品创新能力。此次百亿级投资标志着广药集团迈入高质量发展的新阶段，有望为中国医药行业的转型升级提供示范样本。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/6231.html